Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma
Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.
Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.
The potential of CAR T-cell therapy depends on the results that stem from ongoing clinical trials exploring this type of treatment in these patients, Kumar says. It is too early to speak to the efficacy of CAR T-cell therapy, as well as the immunotherapy agents being studied. Moreover, the toxicity profile has been found to be high in many patients.
Because of the associated toxicities, this may not be the ideal treatment to use in the upfront setting, he adds.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
